15 research outputs found
Learning Curve of Single-Port Laparoscopic Appendectomy for Noncomplicated Acute Appendicitis: A Preliminary Analysis Compared with Conventional Laparoscopic Appendectomy
Balloon-expandable versus self-expanding transcatheter aortic valve replacement for bioprosthetic dysfunction: A systematic review and meta-analysis.
BACKGROUND:Transcatheter aortic valve-in-valve (VIV) procedure is a safe alternative to conventional reoperation for bioprosthetic dysfunction. Balloon-expandable valve (BEV) and self-expanding valve (SEV) are the 2 major types of devices used. Evidence regarding the comparison of the 2 valves remains scarce. METHODS:A systematic review and meta-analysis was conducted to compare the outcomes of BEV and SEV in transcatheter VIV for aortic bioprostheses dysfunction. A computerized search of Medline, PubMed, Embase, and Cochrane databases was performed. English-language journal articles reporting SEV or BEV outcomes of at least 10 patients were included. RESULTS:In total, 27 studies were included, with 2,269 and 1,671 patients in the BEV and SEV groups, respectively. Rates of 30-day mortality and stroke did not differ significantly between the 2 groups. However, BEV was associated with significantly lower rates of postprocedural permanent pacemaker implantation (3.8% vs. 12%; P < 0.001). Regarding echocardiographic parameters, SEV was associated with larger postprocedural effective orifice area at 30 days (1.53 cm2 vs. 1.23 cm2; P < 0.001) and 1 year (1.55 cm2 vs. 1.22 cm2; P < 0.001). CONCLUSIONS:For patients who underwent transcatheter aortic VIV, SEV was associated with larger postprocedural effective orifice area but higher rates of permanent pacemaker implantation. These findings provide valuable information for optimizing device selection for transcatheter aortic VIV
Long-term epidural ketamine, morphine and bupivacaine attenuate reflex sympathetic dystrophy neuralgia
The Effect of Music Therapy on Hospitalized Psychiatric Patients’ Anxiety, Finger Temperature, and Electroencephalography
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond
The
function of the CXCR4/CXCL12 axis accounts for many disease
indications, including tissue/nerve regeneration, cancer metastasis,
and inflammation. Blocking CXCR4 signaling with its antagonists may
lead to moving out CXCR4<sup>+</sup> cell types from bone marrow to
peripheral circulation. We have discovered a novel series of pyrimidine-based
CXCR4 antagonists, a representative (i.e., <b>16</b>) of which
was tolerated at a higher dose and showed better HSC-mobilizing ability
at the maximal response dose relative to the approved drug <b>1</b> (AMD3100), and thus considered a potential drug candidate for PBSCT
indication. Docking compound <b>16</b> into the X-ray crystal
structure of CXCR4 receptor revealed that it adopted a spider-like
conformation striding over both major and minor subpockets. This putative
binding mode provides a new insight into CXCR4 receptor–ligand
interactions for further structural modifications
Discovery of 1‑(2,4-Dichlorophenyl)‑<i>N</i>‑(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)‑1<i>H</i>‑pyrazole-3-carboxamide as a Novel Peripherally Restricted Cannabinoid‑1 Receptor Antagonist with Significant Weight-Loss Efficacy in Diet-Induced Obese Mice
After extensive synthetic
efforts, we found that many structurally
diverse bioisosteres could be generated via derivatizing the C-4 alkyl
chain on the pyrazole ring of compound <b>3</b> (B/P = 1/33)
with different electronegative groups. Especially when a sulfonamide
or sulfamide moiety was added, resulting compounds exhibited not only
potent CB1R activity but also a desired tPSA value over 90 Ă…<sup>2</sup>, a threshold considered to possess a low probability to cross
BBB, leading to the identification of compound <b>4</b> (B/P
= 1/64) as a peripherally restricted CB1R antagonist. Apart from its
significant weight-loss efficacy in DIO mice, compound <b>4</b> also displays 163 clean off-target profiles and is currently under
development for treating obesity and the related metabolic syndrome
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond
The
function of the CXCR4/CXCL12 axis accounts for many disease
indications, including tissue/nerve regeneration, cancer metastasis,
and inflammation. Blocking CXCR4 signaling with its antagonists may
lead to moving out CXCR4<sup>+</sup> cell types from bone marrow to
peripheral circulation. We have discovered a novel series of pyrimidine-based
CXCR4 antagonists, a representative (i.e., <b>16</b>) of which
was tolerated at a higher dose and showed better HSC-mobilizing ability
at the maximal response dose relative to the approved drug <b>1</b> (AMD3100), and thus considered a potential drug candidate for PBSCT
indication. Docking compound <b>16</b> into the X-ray crystal
structure of CXCR4 receptor revealed that it adopted a spider-like
conformation striding over both major and minor subpockets. This putative
binding mode provides a new insight into CXCR4 receptor–ligand
interactions for further structural modifications